Full Length ArticlePanax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro☆,☆☆,☆☆☆,★,★★,★★★
Introduction
Interaction between platelets and injured endothelial cells (ECs) plays a vital role in thrombogenesis [1], [2]. Aspirin (ASA) has potent inhibitory effects on platelet activation by irreversibly acetylating platelet COX-1 and inhibiting thromboxane B2, and also up-regulates the COX-2/prostacyclin (PGI2) pathway in ECs, which contributes to EC survival [3]. However, its effect on platelet adhesion to injured ECs and platelet activation induced by injured ECs remain unclear. Although ASA is commonly used as an effective antiplatelet drug in clinical practice, it is frequently accompanied with “aspirin resistance” in approximately 5.5% to 60% patients [4], so dual antiplatelet regimen (ASA plus clopidogrel) and even triple antiplatelet regimen (ASA plus clopidogrel plus another more powerful antiplatelet agent) have been introduced [5]. Clopidogrel, another commonly used antiplatelet drug, has been also reported with 16.8% to 21% resistance occurrence [6]. Safe and powerful antiplatelet agents are still in need.
Panax notoginseng saponin (PNS) is active compound extracted from pseudo-ginseng including notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rb1 [7]. Many Chinese herbal patent medicines (containing a mix of PNS), such as Xueshuantong injection and Xueshuantong capsule, have been widely used in clinical practice in China for more than 20 years [8]. Previous studies have shown that PNS inhibits platelet activation induced by ADP [9] in vivo and reduces the adhesion of injured ECs induced by ox-LDL in vitro, which was supposed to be derived mainly from the active component notoginsenoside R1 [10], [11]. However, little is known about whether PNS reduces platelet adhesion to injured ECs.
The present experiment was designed to compare the effects of PNS and ASA on platelet adhesion to the injured ECs, and to explore the underlying mechanisms focusing on COX pathway.
Section snippets
Agents
Ox-LDL was purchased from Guangzhou Yiyuan Biotechnology Co, Ltd (Guangzhou, China); ASA and PNS were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China; see HPLC analysis of PNS in Fig. 1); Endothelial culture medium (ECM) was purchased from Cell Signaling Technology (Boston, MA, USA); 6-keto-PGF1α and TXB2 radioimmunoassay kits were purchased from Huaying Biotechnology Institute (Beijing, China); antibodies against CD61 and CD62p,
Platelet CD62p expression
Treatment with ox-LDL led to an increased CD62p expression when compared with the control group (P < 0.05, Fig. 2). Both ASA and PNS treatment decreased CD62p expression significantly compared with the model group (P < 0.05).
Platelet adhesion to HUVECs
Treatment with ox-LDL led to an increased MFI when compared with the control group (P < 0.05, Fig. 3), indicating that HUVEC injury triggered platelet adhesion to HUVECs. Both ASA and PNS treatment decreased the MFI (P < 0.05) compared with the model group. Moreover, PNS treatment
Discussion
The platelet adhesion to ECs is an essential phase of thrombogenesis. The present study showed that (1) PNS was superior to ASA in inhibiting platelet adhesion to injured ECs through modulation of the EC COX-2/PGI2 pathway and down-regulation of platelet COX-1/TXA2 pathway, for the first time to our knowledge; (2) Platelet activation induced by injured ECs exacerbated the EC apoptosis, and ASA protected ECs through its inhibition of platelet activation; (3) ASA inhibited platelet activation
Limitations
There are two limitations in our study should be noted. One is that the ADP signaling pathway in platelet has not been explored with PNS. ADP pathway is of much importance as it is targeted by clopidogrel. The effects of PNS on ADP pathway are worth to be investigated in future. The second limitation is that the combination effect of ASA and PNS on platelet adhesion was not investigated. ASA targets COX pathway in platelet, and the antiplatelet effect of PNS in the present study showed that it
Conclusions
EC protection by ASA is closely associated with its inhibitory effect on platelet activation. PNS is superior to ASA in protecting ECs and in inhibiting platelet adhesion to injured ECs, and the regulation of COX pathway in both ECs and platelets might be the underlying mechanisms of PNS.
Acknowledgments
This work was supported by the National Natural Science Foundation of China (81273933 and 81102722), the Eleven Five-year Plan National Science and Technology Support Project (2006BAI04A01-2), the Jilin Province Major Science and Technology Achievement Transforming Project (11ZDZH005). We would like to thank Editage [http://online.editage.cn/] for English language editing.
References (25)
- et al.
The role of aspirin in cardiovascular prevention: implications of aspirin resistance
J. Am. Coll. Cardiol.
(2008) - et al.
Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis
Am. Heart J.
(2007) - et al.
Prostacyclin protects vascular integrity via PPAR/14-3-3 pathway
Prostaglandins Other Lipid Mediat.
(2015) - et al.
Why do cyclooxygenase-2 inhibitors cause cardiovascular events?
J. Am. Coll. Cardiol.
(2002) - et al.
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation
J. Thromb. Haemost.
(2011) - et al.
Bovine platelets activated by Haemophilus somnus and its LOS induce apoptosis in bovine endothelial cells
Microb. Pathog.
(2005) - et al.
Platelets in inflammation and atherogenesis
Front. Immunol.
(2015) - et al.
Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin
Proc. Natl. Acad. Sci. U. S. A.
(1995) - et al.
Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy
Br. J. Clin. Pharmacol.
(2011) Aspirin and clopidogrel resistance: methodological challenges and opportunities
Vasc. Health Risk Manag.
(2010)
Effects of panax notoginseng combinating with dual antiplatelet drugs on the major adverse cardiovascular events in pafients undergoing percutaneous coronary intervention procedure
Chin. Med.
Cited by (43)
A Gellan Gum/Sodium Alginate-based gastric-protective hydrogel loaded with a combined herbal extract consisting of Panax notoginseng, Bletilla striata and Dendrobium officinale
2023, International Journal of Biological MacromoleculesA sensitive LC-MS/MS method-based pharmacokinetic study of fifteen active ingredients of Yindan Xinnaotong soft capsule in rats and its potential mechanism in the treatment of cardiovascular diseases
2023, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesNetwork pharmacology reveals the targets and mechanism for Panax notoginseng (Burk.) F. H. Chen against venous thromboembolism
2022, Pharmacological Research - Modern Chinese MedicineTraditional uses, chemical diversity and biological activities of Panax L. (Araliaceae): A review
2020, Journal of Ethnopharmacology
- ☆
Prof. Dazhuo Shi has made substantial contributions to the conception and design of this study, with revising and final approve of the article.
- ☆☆
Assoc. Prof. Mei Xue has made substantial contributions to the design of this study, with data analysis of the study and revising of the article.
- ☆☆☆
Mingming Wang has contributed to the conduction and data analysis of this study, and the article drafting.
- ★
Yu Miao and Na Kou have contributed to the umbilical preparation and HUVEC culture.
- ★★
Yonggang Xu has contributed to FACS detection and analysis.
- ★★★
Lin Yang and Ying Zhang have contributed to the drug material supply and blood sampling and procession.
- 1
Ming-ming Wang and Mei Xue are co-first authors.